Product Introduction
Bioactivity


英文名: Traxanox TFA

描述: Traxanox TFA 是一种可口服的利尿剂。Traxanox TFA 在体外增强小鼠腹膜巨噬细胞或大鼠腹膜多形核白细胞对酵母颗粒的吞噬作用。Traxanox TFA 对抑制BALB/c小鼠抗体产生的恢复作用。

体内活性: Traxanox TFA (100 mg/kg, p.o.) showed a tendency to suppress dextran edema and cotton pellet granuloma formation in adjuvant arthritis (AA) in rats. In experimental models of delayed-type hypersensitivity (DTH), Traxanox TFA (100 mg/kg, p.o.) inhibited the accumulation of the exudate and the leucocyte migration in B. pertussis-induced pleurisy in rats. Traxanox TFA (50 mg/kg) did not show any effect on AA in Lewis rats when administered orally for 21 days after the adjuvant inoculation, but the combined administration of Traxanox TFA with hydrocortisone (10 mg/kg, p.o.) or indomethacin (0.25 mg/kg, p.o.) resulted in a synergistic inhibition of AA. When the administration of Traxanox TFA was started 21 days before the adjuvant inoculation, it inhibited AA in a dose-dependent manner (50-100 mg/kg, p.o.). On the other hand, Traxanox TFA (100 mg/kg, p.o.) enhanced the concanavalin A-induced DTH-like skin reaction in guinea pigs. These results indicate that the mode of action of Traxanox TFA on inflammatory responses resembles that of D-penicillamine or levamisole, so it may prove to be clinically effective in treating rheumatoid arthritis.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 6.25 mg/mL (15.11 mM)


关键字: Traxanox TFA

相关库: Bioactive Compounds Library Max | Bioactive Compound Library